Cardiovascular diseases are responsible for significant mortality.
Their cause is multifactorial: aging, lifestyle, diseases (diabetes, chronic kidney failure).
Among the aggravating factors, the presence of calcifications in the vessels and heart valves greatly increases the cardiovascular risk. The mechanisms behind these calcifications are not yet fully known and, to date, there are no effective therapies to stop or slow their development.
This Unit works to improve pathophysiology knowledge and therapeutic management of these calcifications.
1. Molecular mechanisms involved in calcification processes and associated factors/markers.
2. Hemodynamic and structural consequences of cardiovascular calcifications in animals and humans.
3. Therapeutic strategies to prevent and treat these calcifications.
This Unit uses conventional biochemistry and molecular biology techniques of research:
• Cell culture
• Western Blot
• Infrared, Immunohistochemistry
• Flow cytometry
• Animal testing
Example(s) of projects
Exploration of the role of vasorine in vascular disorders and calcification.
MP3CV Holder: Isabelle Six
Budget: €537 K (MP3CV: €70 K); Partners: Université Paris Descartes (carrier), UPJV (MP3CV), Max Planck Institute for Molecular Genetics, PARCC Paris Centre de Research Cardiovascular.
2. CALARTOS Project “Bone Arterial Calcification: Interest in Surgical Management of Long Bone Loss Using Masks”:
Exploration of reconstructive neo-synthesis, and in particular the molecular mechanisms of the action of the membrane induced during osteosynthesis; substitution of this arterial tissue-induced membrane to generate a new bone reconstruction medical practice.
MP3CV Wearer: Romuald Mentaverri
Partners: UPJV (carrier)
3. Project H2020 CaSR “Calcium-Sensing Receptor Therapeutics for Non Communicable Diseases”:
Increase knowledge of the role of the calcium-sensitive receptor (CaSR) in the pathogenesis of serious non-transmissible diseases (Alzheimer’s disease, cardiovascular diseases, type 2 diabetes, cancers, sarcopenia), and train young researchers in scientific excellence in the field of cellular signalling.
MP3CV carrier : Romuald Mentaverri
MP3CV budget: €262k
Example(s) of publications
2. VALIDATION AND APPLICATION OF A HPLC-DAD METHOD FOR ROUTINE THERAPEUTIC DRUG MONITORING OF CEFTOBIPROLE.Lima B, Bodeau S, Quinton MC, Leven C, Lemaire-Hurtel AS, Bennis Y.Antimicrob Agents Chemother. 2019 Apr 22. 🡭
3.The pharmacokinetic challenge of voriconazole therapy for cerebral aspergillosis in patients treated with ibrutinib.Nyga R, Simon L, Chouaki T, Delette C, Bennis Y, Joseph C, Marolleau JP, Slama M, Zogheib E, Maizel J.Crit Care. 2019 Mar 12;23(1):88. 🡭
4. Characteristics and Prognosis of Patients With Moderate Aortic Stenosis and Preserved Left Ventricular Ejection Fraction. Delesalle G, Bohbot Y, Rusinaru D, Delpierre Q, Maréchaux S, Tribouilloy C.J Am Heart Assoc. 2019 Mar 19;8(6):e011036. 🡭
5. Dipeptidyl Peptidase-4 Inhibition Prevents Vascular Calcification by Potentiating the Insulin-Like Growth Factor-1 Signaling Pathway. Varennes O, Mary A, Bricca G, Kamel S, Bellien J.JACC Basic Transl Sci. 2019 Feb 25;4(1):113-115. 🡭
All publications can be found here : 🡭
International : Max Planck Institute for Molecular Genetics (Germany)
You can find the complete list of equipment here : 🡭
Affiliated institutions / organisations
Regional strategic areas of activity
- Chemistry and Materials
- Organic chemistry
- Health and Nutrition
- Food ingredients
- Medicine of the future: new health equipment and e-health
- New therapeutic approaches
- Prevention, well-being and the silver economy